Zhanhong Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8044068/publications.pdf

Version: 2024-02-01

1040056 940533 23 251 9 16 citations h-index g-index papers 23 23 23 501 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	miR-181b promotes chemoresistance in breast cancer by regulating Bim expression. Oncology Reports, 2016, 35, 683-690.	2.6	56
2	Clinicopathological Characteristics of Mucinous Breast Cancer: A Retrospective Analysis of a 10-Year Study. PLoS ONE, 2016, 11, e0155132.	2.5	35
3	Expression of cluster of differentiation 34 and vascular endothelial growth factor in breast cancer, and their prognostic significance. Oncology Letters, 2015, 10, 723-729.	1.8	24
4	Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling. Molecular Genetics & Enomic Medicine, 2020, 8, e1079.	1.2	23
5	PET/CT Imaging for Monitoring Recurrence and Evaluating Response to Treatment in Breast Cancer. Advances in Clinical and Experimental Medicine, 2016, 25, 377-382.	1.4	20
6	Downregulation of miRâ€'200câ€'3p contributes to the resistance of breast cancer cells to paclitaxel by targeting SOX2. Oncology Reports, 2018, 40, 3821-3829.	2.6	18
7	Everolimusâ€containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study. Cancer Medicine, 2019, 8, 5544-5553.	2.8	16
8	ADAMTS9-AS1 Constrains Breast Cancer Cell Invasion and Proliferation via Sequestering miR-301b-3p. Frontiers in Cell and Developmental Biology, 2021, 9, 719993.	3.7	12
9	Role of estrogen receptor in breast cancer cell gene expression. Molecular Medicine Reports, 2016, 13, 4046-4050.	2.4	11
10	Prognostic significance of mammary Paget's disease in Chinese women: a 10 year, population-based, matched cohort study. OncoTargets and Therapy, 2018, Volume 11, 8319-8326.	2.0	10
11	Bioinformatics identification of dysregulated microRNAs in triple negative breast cancer based on microRNA expression profiling. Oncology Letters, 2018, 15, 3017-3023.	1.8	9
12	Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study Journal of Clinical Oncology, 2021, 39, 1037-1037.	1.6	7
13	Treatment after Progression on Fulvestrant among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study. Scientific Reports, 2019, 9, 1710.	3.3	4
14	Long-term tolerance and cardiac function in breast cancer patients receiving trastuzumab therapy. Oncotarget, 2017, 8, 2069-2075.	1.8	4
15	BRCANet: A deep hybrid network in predicting BRCA1/2 gene mutation of breast cancer with dynamic contrast-enhanced breast MRI Journal of Clinical Oncology, 2022, 40, e13576-e13576.	1.6	1
16	Apatinib combined with chemotherapy versus single chemotherapy in HER-2 negative advanced breast cancer: A randomized, controlled, open-label phase II study Journal of Clinical Oncology, 2022, 40, 1072-1072.	1.6	1
17	Rs1008805 polymorphism of CYP19A1 gene is associated with the efficacy of hormone therapy in stage lâ€'ll and operable stage III breast cancer. Oncology Letters, 2017, 14, 6156-6162.	1.8	0
18	A retrospective study of 21-gene recurrence score assay compared with clinicopathological markers in node-negative, hormone receptor-positive, HER2-negative breast cancer Journal of Clinical Oncology, 2017, 35, e12023-e12023.	1.6	0

#	Article	IF	CITATIONS
19	Expression of androgen receptor and epidermal growth factor receptor in invasive breast cancer: A retrospective study of 1,438 patients from China Journal of Clinical Oncology, 2017, 35, e12587-e12587.	1.6	0
20	Assessment of PD-L1 expression in circulating tumor cells in patients with breast cancer Journal of Clinical Oncology, 2020, 38, e13001-e13001.	1.6	O
21	Apatinib to prolong overall survival from recurrence to death in metastatic breast cancer: A single-center experience from east China Journal of Clinical Oncology, 2020, 38, e13090-e13090.	1.6	O
22	Patient-reported outcomes for measuring the quality of life in advanced breast cancer treated with third-line and beyond chemotherapy-based regimens: A national cross-sectional study Journal of Clinical Oncology, 2022, 40, 1103-1103.	1.6	0
23	Identified potential pathogenic variants of BARD1 in 1449 Chinese high-risk breast cancer patients Journal of Clinical Oncology, 2022, 40, e22525-e22525.	1.6	0